National Academies Press: OpenBook

Issues in Risk Assessment (1993)

Chapter: 2.3 Variation in Carcinogen Potency

« Previous: 2.2 Carcinogenic Potency Database (CPDB)
Suggested Citation:"2.3 Variation in Carcinogen Potency." National Research Council. 1993. Issues in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/2078.
×

1986b). When the level of exposure was not constant throughout the study period, a time-weighted average daily dose was used to determine the TD50. Although more precise methods of estimating carcinogenic potency with time-dependent exposure patterns are available (Murdoch & Krewski, 1988), this is not critical for our present purposes (cf. Murdoch et al., 1992).

The CPDB includes data on over 3700 experiments on 975 different chemicals conducted under the National Cancer Institute/National Toxicology Program and by other investigators who have reported their results in the scientific literature (Gold et al., 1989). For each chemical, the CPDB may include studies done on different sexes, species and strains; by various routes of exposure; or under other experimental conditions. For each experiment, the doses and crude tumor response rates for each lesion demonstrating evidence of a dose-related effect are provided, thereby affording the opportunity for secondary analyses of the experimental results.

2.3 Variation in Carcinogen Potency

The CPDB includes data on potent chemical carcinogens such as 2,3,7,8-tetraclorodibenzo-p-dioxin (TCDD), as well as less potent compounds such as DDT. Gold et al. (1984) noted that the TD50 value in the CPDB for chemicals inducing tumors in rats varied by seven orders of magnitude or 10 million-fold.

In studying the distribution of carcinogenic potency, Rulis (1986) noted that the TD50 values for 343 rodent carcinogens selected from the CPDB were roughly lognormally distributed. (In cases where more than one experiment was done on the same chemical or where more than one lesion was dose-related in a single study, the minimum TD50 value was used in this analysis.) Similar distributions have been observed using other subsets of the CPDB (Krewski et al., 1990b). For example, consider the distribution of TD50 values shown in Figure 1a for 191 of the 217 compounds considered previously by Krewski et al. (1990b). These compounds were selected to satisfy a number of criteria, including the requirements that the experiment have at least two doses in addition to unexposed controls and demonstrate clear evidence of carcinogenicity. The 26 experiments omitted from the current analysis included only one

Suggested Citation:"2.3 Variation in Carcinogen Potency." National Research Council. 1993. Issues in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/2078.
×

FIGURE 1a Variation in carcinogenic potency of 191 chemical carcinogens selected from the CPDB.

Suggested Citation:"2.3 Variation in Carcinogen Potency." National Research Council. 1993. Issues in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/2078.
×
Page 117
Suggested Citation:"2.3 Variation in Carcinogen Potency." National Research Council. 1993. Issues in Risk Assessment. Washington, DC: The National Academies Press. doi: 10.17226/2078.
×
Page 118
Next: 2.4 Classification of Carcinogens »
Issues in Risk Assessment Get This Book
×
Buy Paperback | $65.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The scientific basis, inference assumptions, regulatory uses, and research needs in risk assessment are considered in this two-part volume.

The first part, Use of Maximum Tolerated Dose in Animal Bioassays for Carcinogenicity, focuses on whether the maximum tolerated dose should continue to be used in carcinogenesis bioassays. The committee considers several options for modifying current bioassay procedures.

The second part, Two-Stage Models of Carcinogenesis, stems from efforts to identify improved means of cancer risk assessment that have resulted in the development of a mathematical dose-response model based on a paradigm for the biologic phenomena thought to be associated with carcinogenesis.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!